|Zack’s Notes Keryx ($KERX) Uptrend and 67% Change in 52 Weeks|
Zacks.com, a leader in investment research, has aptly noted the recent uptrend in the share price of Keryx Biopharmaceuticals over the last several weeks. Zack’s “SmarTrend” analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time.
According to Zack’s commentary on April 5, 2011,
“In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $3.03 and a high of $6.67 and are now at $5.05, which is 67% above that low price.
Keryx Biopharmaceuticals is currently above its 50-day moving average of $4.19 and above its 200-day moving average of $4.38. Look for these moving averages to climb to confirm the company's upward momentum.
In the last five trading sessions, the 50-day MA has climbed 1.72% while the 200-day MA has risen 0.28%.”
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Share This Post: